A Phase 2 interventional study of Abiraterone and Prednisone in Prostate Neoplasms and Prostate Cancer, sponsored by Janssen-Ortho Inc., Canada. Completed at 2 sites in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-25.
Sponsored by Janssen-Ortho Inc., Canada (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing abiraterone in Prostatic Neoplasms — 17 open to participants now, 37 under way, 5 of them phase 3. abiraterone · Prostatic Neoplasms.
Among the 126 studies testing abiraterone in Prostatic Neoplasms, this one is the 96th largest by enrollment, is one of 6 that started in 2011, is one of 79 in phase 2, and was the 19th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →17 of the 126 studies testing abiraterone in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
University of Nebraska · Sites in United States
Ages 30+ · Men only
Mayo Clinic · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States, Australia, France and 4 more countries
Ages 18+ · Men only
SMED Clinical Research · Sites in Argentina, Spain
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
abiraterone: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 90 · Phase 3 12 · Phase 4 4
First in 2005; this study’s year is marked. 6 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 51 across the 126 interventional studies. Of the 75 that completed or were terminated, 47 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen-Ortho Inc., Canada, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Ortho Inc., Canada is the lead sponsor of 22 studies on the registry; none are open to participants now.
88 studies in Prostatic Neoplasms by Johnson & Johnson: 9 open now, 23 under way, 9 of them phase 3. Of 58 finished, 24 (41%) have results posted.
Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 61st largest by enrollment of the 68 interventional ones that give a count, is one of 4 that started in 2011, is one of 20 in phase 2, and was the 24th registered.
Johnson & Johnson’s Prostatic Neoplasms studies by the year they started, since 1995.
10 of the studies testing abiraterone in Prostatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT06173362University of California, DavisAbiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer | 2026-11 |
| NCT07299292SMED Clinical ResearchCastration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2) | 2026-12-31 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
| NCT03902951Jonsson Comprehensive Cancer CenterAntiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | 2027-01-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 126 studies testing abiraterone in Prostatic Neoplasms, from their registry updates:
Among Johnson & Johnson’s 88 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to establish the safety profile of oral (by mouth) abiraterone acetate and oral prednisone following short-term administration after standardized low-fat or high-fat meals to patients with metastatic (spreading) castration-resistant prostate cancer (mCRPC).
This is a multicenter, open-label study of 24 (up to a total of 28) men to assess the short-term safety of oral abiraterone acetate 1 g and oral prednisone 5 mg twice daily administered in the modified fasted state and after meals of various fat contents. All patients will take daily abiraterone acetate for the first 7 days in the modified fasted state (no food for 2 hours before and 1 hour after the dose). In Cohort 1, up to 6 evaluable patients will take abiraterone acetate daily for 7 days after a standardized low-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14; or, in Cohort 2, up to 6 evaluable patients will take abiraterone acetate daily for 7 days after a standardized high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. All patients will then continue to take abiraterone acetate daily in the modified fasted state starting on Cycle 1 Day 15 until disease progression. Toxicity related to dosing after the low-fat or high-fat meals is defined as Grade 3 or higher AEs of special interest; or Grade 3 or higher serious adverse events (SAEs) that occur during the food safety evaluation period. Cohort 2 may be expanded to a total of 18 evaluable patients if deemed to be safe. Decisions regarding the escalation of cohort or expansion of cohorts will be made by a study evaluation team. Pharmacokinetic evaluation for each cohort will be performed on Cycle 1 Days 7 and 14 at predose and multiple timepoints postdose over 24 hours; Cycle 1 Days 8 and 11 at 2 hours following abiraterone acetate dose administration. Abiraterone acetate, 1 g (four 250-mg tablets) orally (taken by mouth) once daily. Patients may take abiraterone acetate until progression of clinical disease. Prednisone, 5 mg, orally, twice a day.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive abiraterone acetate at a starting dose of 1,000 milligram (mg) once daily for 7 days post 30-minutes of a standardized low-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
Drug: Abiraterone · Drug: Prednisone
Participants will receive abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
Drug: Abiraterone · Drug: Prednisone
Participants will receive abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized low-fat meal and high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14.
Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
Number of Participants With Grade 3 or Higher Adverse Events (AEs) of Special Interest or Grade 3 or Higher Serious AEs Due to Study Medication
AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events.
Time frame: Postdose on Cycle 1 Day 8 to predose on Cycle 2 Day 1
Maximum Observed Plasma Concentration (Cmax) of Abiraterone
The table below shows mean Cmax of Abiraterone. The Plasma Concentration (Cmax) is defined as maximum observed analyte concentration.
Time frame: Day 7 and Day 14
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Abiraterone
The table below shows median Tmax of Abiraterone. The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.
Time frame: Day 7 and Day 14
Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)
The table below shows mean AUC24h. The Area Under the Plasma Concentration-Time Curve (AUC) is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption.
Time frame: Day 7 and Day 14
The study was conducted from 29 September 2011 to 29 May 2013. Participants were recruited at 2 study centers in Canada.
| Milestone | Abiraterone+Prednisone (Low-fat Meal) | Abiraterone+Prednisone (High-fat Meal) |
|---|---|---|
| Started | 7 | 18 |
| Completed food safety evaluation | 6 | 18 |
| Completed | 3 | 4 |
| Not completed | 4 | 14 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Progressive disease | 3 | 6 |
| Withdrew: Screen failure | 0 | 1 |
| Withdrew: Reason not specified | 0 | 6 |
AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events.
| Participants | Abiraterone+Prednisone (Low-fat Meal) | Abiraterone+Prednisone (High-fat Meal) |
|---|---|---|
| Number of Participants With Grade 3 or Higher Adverse Events (AEs) of Special Interest or Grade 3 or Higher Serious AEs Due to Study Medication | 0 | 0 |
The table below shows mean Cmax of Abiraterone. The Plasma Concentration (Cmax) is defined as maximum observed analyte concentration.
| ng/mL | Abiraterone+Prednisone (Low-fat Meal) | Abiraterone+Prednisone (High-fat Meal) |
|---|---|---|
| Day 7 | 218 ± 168 | 196 ± 234 |
| Day 14 | 265 ± 229 | 342 ± 289 |
The table below shows median Tmax of Abiraterone. The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.
| hours | Abiraterone+Prednisone (Low-fat Meal) | Abiraterone+Prednisone (High-fat Meal) |
|---|---|---|
| Day 7 | 2 ± 1.0 - 8.1 | 2 ± 0.5 - 6.0 |
| Day 14 | 2.5 ± 1.0 - 3.0 | 4.0 ± 3.0 - 10.0 |
The table below shows mean AUC24h. The Area Under the Plasma Concentration-Time Curve (AUC) is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption.
| ng*h/mL | Abiraterone+Prednisone (Low-fat Meal) | Abiraterone+Prednisone (High-fat Meal) |
|---|---|---|
| Day 7 | 1271 ± 1279 | 973 ± 667 |
| Day 14 | 1264 ± 963 | 1992 ± 720 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abiraterone+Prednisone (Low-fat Meal) | — | 4/7 (57.1%) | 7/7 (100%) |
| Abiraterone+Prednisone (High-fat Meal) | — | 4/18 (22.2%) | 18/18 (100%) |
| Event | Abiraterone+Prednisone (Low-fat Meal) | Abiraterone+Prednisone (High-fat Meal) |
|---|---|---|
| Myocardial InfarctionCardiac disorders | 1/7 | 0/18 |
| VomitingGastrointestinal disorders | 1/7 | 0/18 |
| Lobar PneumoniaInfections and infestations | 1/7 | 0/18 |
| PneumoniaInfections and infestations | 1/7 | 1/18 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/7 | 0/18 |
| Bone PainMusculoskeletal and connective tissue disorders | 1/7 | 0/18 |
| Muscular WeaknessMusculoskeletal and connective tissue disorders | 1/7 | 0/18 |
| DeliriumPsychiatric disorders | 1/7 | 1/18 |
| Small Intestinal ObstructionGastrointestinal disorders | 0/7 | 1/18 |
| FatigueGeneral disorders | 0/7 | 1/18 |
| Event | Abiraterone+Prednisone (Low-fat Meal) | Abiraterone+Prednisone (High-fat Meal) |
|---|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 5/7 | 7/18 |
| FatigueGeneral disorders | 3/7 | 11/18 |
| ConstipationGastrointestinal disorders | 4/7 | 7/18 |
| DiarrhoeaGastrointestinal disorders | 4/7 | 6/18 |
| NauseaGastrointestinal disorders | 4/7 | 7/18 |
| Oedema PeripheralGeneral disorders | 4/7 | 6/18 |
| Decreased AppetiteMetabolism and nutrition disorders | 4/7 | 8/18 |
| Back PainMusculoskeletal and connective tissue disorders | 4/7 | 7/18 |
| Bone PainMusculoskeletal and connective tissue disorders | 4/7 | 2/18 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/7 | 8/18 |
| Age, Continuous(years) | Abiraterone+Prednisone (Low-fat Meal) | Abiraterone+Prednisone (High-fat Meal) | Total |
|---|---|---|---|
| Mean | 75.1 ± 11.01 | 69.1 ± 7.26 | 70.8 ± 8.67 |
| Sex: Female, Male(Participants) | Abiraterone+Prednisone (Low-fat Meal) | Abiraterone+Prednisone (High-fat Meal) | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 7 | 18 | 25 |
The record gives a start of Oct 2011, a primary completion of Apr 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abiraterone · Prednisone